The ATTAIN-1 trial tested orforglipron in 3,127 adults with obesity or overweight with a weight-related condition
Injection therapies may be discussed for energy support, nutrient optimization, metabolism support, and wellness goals depending on the specific injection and provider guidance
With a litany of cardiovascular outcome trials in the past decade alone showcasing the CV benefits of SGLT2 inhibitors and GLP-1 receptor agonists, the American Diabetes Association and European Association for the Study of Diabetes have created a much improved recommendation for treatment progression, according to Rosenstock, who noted that despite this improvement, the recommendation is still for sequential and not simultaneous combination therapies
You can use a cooler for transport, but you must be careful not to let the medication touch the ice directly
Our guide to GLP-1 microdosing for menopause weight gain dives deeper into this connection
E.BendersM.GonzalezF.BearerC.et al (2023)
